New Statin-CBD combo drug enters first human safety trial

NCT ID NCT06615284

Completed Disease control Sponsor: Indication Bioscience LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested the safety of Atorvo+™, a new drug that combines the common cholesterol-lowering medication atorvastatin with cannabidiol (CBD). The trial involved 24 healthy adults aged 40-75 to see how the body processes the drug and if it causes any side effects. The goal is to find a better way to manage cholesterol and lower the risk of heart disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atorvo+™ (a combination of atorvastatin and cannabidiol (CBD))
What this could lead to: If successful, this could lead to a new treatment option for managing cholesterol and reducing heart disease risk.
What could go wrong: This is an early Phase 1 safety study in only 24 healthy adults, so it does not yet test effectiveness. Side effects like muscle pain or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY HEART DISEASE DYSLIPIDEMIAS

Contacts and locations

Locations

Nucleus Network

Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.